MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today announced the appointment of Mr Brett Mitchell to the Board of Directors. Mr Mitchell will join the Board as a Non-Executive Director with the appointment effective today, 14 June 2024.
Mr. Mitchell is an experienced corporate finance executive with more than 15 years of experience in ASX listed companies leading transactions in the biopharmaceutical, mining, energy and tech industries. He has been involved in the founding, financing, and management of both private and publicly-listed companies, including recently as a director of ASX listed lithium developer Delta Lithium Ltd (DLI), the dual ASX-LSE listed medical cannabis company Argent Biopharma Ltd (RGT), and is currently Executive Chairman of ASX listed Javelin Minerals Ltd (ASX:JAV) and Non-Executive Chairman of Uvre Limited (ASX :UVA). Additionally, Mr Mitchell has founded two financial advisory services businesses and brings a track record of capital raising and corporate strategy to Imagion.
“I am pleased to be joining the Imagion Biosystems Board because I believe I can contribute to the company at this time as it looks to reestablish itself and get back on track to create value with its innovative medical imaging technology”, said Mr Mitchell.
Bob Proulx, Executive Chairman of Imagion Biosystems said, “We are very pleased to welcome Brett as a non-executive director of Imagion. Brett’s experience in the ASX capital markets will be very helpful as we chart our path forward.”
With the appointment of Mr. Mitchell, who resides in Australia, IBX will be in compliance with section 201A(2) of the Corporations Act, and as such is expecting the ASX will re-instate IBX to official quotation allowing trading to resume. Additionally, the Company notes that a spill resolution was passed at its recent Annual General Meeting of shareholders and the Company intends to hold a meeting as required to reelect the Board of Directors.
About Imagion Biosystems
Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems’ MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.
For more information, visit https://imagionbiosystems.com/investor-hub/
Authorisation & Additional information
This announcement was authorised by the Board of Imagion Biosystems Limited.
